Sy Mukherjee, Fortune

Sy Mukherjee

Fortune

New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Learn more here

Recent:
  • Fortune

Recent articles by Sy:

Sanofi, Regeneron Win FDA Approval for Eczema Drug With Multi-Billion Dollar Potential

The FDA has approved eczema treatment Dupixent from Sanofi Genzyme and partner Regeneron. It could bring in billions in sales. → Read More

The Republican-Dominated Kansas Legislature Just Approved a Major Obamacare Provision

Medicaid expansion endorsed after Trumpcare's failure. → Read More

The Patent Battle Over Revolutionary CRISPR Gene-Editing Tech Just Went Global

CRISPR Therapeutics, U.C. Berkeley, and affiliated groups will receive a broad CRISPR patent for the gene editing tech in Europe. → Read More

Trump Is Slashing FDA Rules. Why Isn’t Big Pharma Excited?

Donald Trump’s promise to streamline FDA regulations is less popular with the pharmaceutical industry than you might think. → Read More

Here’s How Health Care Stocks Are Responding to Trumpcare’s Demise

Trumpcare's failure on Friday sent hospital stocks soaring. But the AHCA's demise affected other healthcare stocks differently. → Read More

Trumpcare May Have Died But That Doesn’t Mean Obamacare Is Safe

The GOP pulled the American Health Care Act (AHCA) from the House in a stunning defeat. But Republicans can still undermine Obamacare. → Read More

Secretive Google-Backed Startup Calico Just Struck a New Biotech Partnership

Calico, the life sciences research outfit backed by Google, has struck a deal with biotech C4 Therapeutics to develop cancer drugs. → Read More

Donald Trump Is Pressuring Republicans Into Passing Trumpcare by the End of the Day

Donald Trump issued the House GOP an ultimatum: vote on the AHCA today or Obamacare stays. He's using Twitter to browbeat lawmakers. → Read More

Trumpcare Is Deeply Unpopular Ahead of Its Crucial Congressional Vote

Congress has decided to delay a vote on the American Health Care Act (AHCA). But the legislation is still extremely unpopular. → Read More

How Smartphones Can Actually Improve Male Fertility

A new smartphone app that can be used to analyze sperm could become a groundbreaking, cheap new method of male fertility testing. → Read More

An FDA Program Incentivizing Rare Disease Drugs Will Be Investigated for Abuses

The GAO will investigate the FDA orphan drug program's potential for abuse such as price gouging following Congressional requests. → Read More

Trumpcare Is Worse Than Simply Repealing Obamacare

To the tune of 1 million more uninsured Americans. → Read More

How Zocdoc’s New Machine Learning Search Engine Makes Medicine More Human

It makes it easier to find the kind of doctor you might need. → Read More

Donald Trump Just Sent Drug Stocks Tumbling—Again

President Donald Trump's latest drug price comments sent biotech stock indices into declines. But the effects weren't too severe. → Read More

How Digital Health Could Help End the Opioid Addiction Crisis

A digital health tool not being used in the fight on the opioid addiction epidemic: electronic prescriptions, says Atul Gawande. → Read More

One Doctor’s Prescription for the Health Tech Industry

A Northwestern University physician and professor gives some advice to health technology and digital health startups. → Read More

Two Gates Foundation Vets Just Raised $200 Million for a Biotech and Digital Health Fund

It's meant to fuel big data and genomics-focused firms. → Read More

These 3 Republicans Just Became the First Ones to Vote Against Trumpcare

They're the first official GOP detractors on the Obamacare replacement. → Read More

Apple’s Medical Research App Just Proved That It Really Works

Apple's ResearchKit has proven to be as accurate as conventional studies in a two-year trial of asthma patients. → Read More

Allergan Just Got Access to Groundbreaking Gene-Editing Treatments for Eye Diseases

Allergan and Editas struck a research partnership that gives Allergan access to experimental CRISPR treatments for eye diseases. → Read More